nodes	percent_of_prediction	percent_of_DWPC	metapath
Fenoldopam—ADRA1D—polycystic ovary syndrome	0.353	0.412	CbGaD
Fenoldopam—ADRA1B—polycystic ovary syndrome	0.301	0.351	CbGaD
Fenoldopam—ADRA1A—polycystic ovary syndrome	0.203	0.237	CbGaD
Fenoldopam—ADRA1D—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.11e-05	7.82e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—GAB1—polycystic ovary syndrome	1.11e-05	7.82e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.11e-05	7.8e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.11e-05	7.78e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—SLC2A4—polycystic ovary syndrome	1.1e-05	7.75e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—LEP—polycystic ovary syndrome	1.1e-05	7.71e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.1e-05	7.7e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.1e-05	7.7e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—FGF18—polycystic ovary syndrome	1.09e-05	7.66e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—YAP1—polycystic ovary syndrome	1.09e-05	7.63e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PGR—polycystic ovary syndrome	1.09e-05	7.63e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—AKR1C3—polycystic ovary syndrome	1.08e-05	7.6e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—RBP4—polycystic ovary syndrome	1.08e-05	7.6e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—GHRL—polycystic ovary syndrome	1.08e-05	7.59e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—PLAT—polycystic ovary syndrome	1.08e-05	7.59e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.08e-05	7.58e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—GAB1—polycystic ovary syndrome	1.07e-05	7.53e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PGR—polycystic ovary syndrome	1.07e-05	7.51e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.07e-05	7.5e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—CYP17A1—polycystic ovary syndrome	1.07e-05	7.48e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.07e-05	7.48e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—INSR—polycystic ovary syndrome	1.06e-05	7.47e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling by GPCR—POMC—polycystic ovary syndrome	1.06e-05	7.45e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—PRL—polycystic ovary syndrome	1.06e-05	7.43e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—NGFR—polycystic ovary syndrome	1.05e-05	7.4e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling by GPCR—POMC—polycystic ovary syndrome	1.05e-05	7.35e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—PRL—polycystic ovary syndrome	1.05e-05	7.34e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.04e-05	7.31e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—CYP19A1—polycystic ovary syndrome	1.04e-05	7.29e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Hemostasis—VEGFA—polycystic ovary syndrome	1.04e-05	7.27e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—ATF1—polycystic ovary syndrome	1.03e-05	7.24e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—INSR—polycystic ovary syndrome	1.03e-05	7.2e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.02e-05	7.16e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.01e-05	7.1e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—YAP1—polycystic ovary syndrome	1.01e-05	7.09e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PLAT—polycystic ovary syndrome	1.01e-05	7.09e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—GHRL—polycystic ovary syndrome	1.01e-05	7.09e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.01e-05	7.07e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.01e-05	7.06e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1e-05	7.05e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1e-05	7.03e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—GAB1—polycystic ovary syndrome	9.97e-06	7e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	9.96e-06	6.99e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PLAT—polycystic ovary syndrome	9.94e-06	6.98e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—GHRL—polycystic ovary syndrome	9.94e-06	6.98e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.91e-06	6.96e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PGR—polycystic ovary syndrome	9.86e-06	6.92e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—IRS1—polycystic ovary syndrome	9.81e-06	6.88e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	9.75e-06	6.84e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	9.73e-06	6.83e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Hemostasis—VEGFA—polycystic ovary syndrome	9.67e-06	6.79e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—ATF1—polycystic ovary syndrome	9.64e-06	6.76e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	9.6e-06	6.73e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—GPCR downstream signaling—POMC—polycystic ovary syndrome	9.58e-06	6.72e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—INSR—polycystic ovary syndrome	9.53e-06	6.69e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—NGFR—polycystic ovary syndrome	9.52e-06	6.68e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PGR—polycystic ovary syndrome	9.5e-06	6.67e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—ATF1—polycystic ovary syndrome	9.48e-06	6.66e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—POMC—polycystic ovary syndrome	9.46e-06	6.64e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—POMC—polycystic ovary syndrome	9.44e-06	6.63e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—PRL—polycystic ovary syndrome	9.44e-06	6.62e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	9.4e-06	6.6e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—INS—polycystic ovary syndrome	9.39e-06	6.59e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	9.35e-06	6.57e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—GNAS—polycystic ovary syndrome	9.32e-06	6.54e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—GNAS—polycystic ovary syndrome	9.27e-06	6.51e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	9.25e-06	6.49e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—TH—polycystic ovary syndrome	9.23e-06	6.48e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	9.21e-06	6.46e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—GNAS—polycystic ovary syndrome	9.19e-06	6.45e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—GHRL—polycystic ovary syndrome	9.17e-06	6.43e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PLAT—polycystic ovary syndrome	9.17e-06	6.43e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.09e-06	6.38e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—IGF1—polycystic ovary syndrome	9.08e-06	6.37e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—AKT2—polycystic ovary syndrome	9.08e-06	6.37e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	9.06e-06	6.36e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	8.97e-06	6.3e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.95e-06	6.28e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	8.92e-06	6.26e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—NGFR—polycystic ovary syndrome	8.89e-06	6.24e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.88e-06	6.23e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—POMC—polycystic ovary syndrome	8.84e-06	6.2e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—NCOR1—polycystic ovary syndrome	8.83e-06	6.2e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—GHRL—polycystic ovary syndrome	8.83e-06	6.2e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PLAT—polycystic ovary syndrome	8.83e-06	6.2e-05	CbGpPWpGaD
Fenoldopam—DRD2—GPCR downstream signaling—POMC—polycystic ovary syndrome	8.83e-06	6.2e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	8.83e-06	6.19e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PRL—polycystic ovary syndrome	8.81e-06	6.19e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.76e-06	6.15e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—NGFR—polycystic ovary syndrome	8.75e-06	6.14e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—ATF1—polycystic ovary syndrome	8.74e-06	6.14e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—NRG1—polycystic ovary syndrome	8.71e-06	6.12e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—POMC—polycystic ovary syndrome	8.7e-06	6.1e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PRL—polycystic ovary syndrome	8.67e-06	6.09e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.62e-06	6.05e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—NRG1—polycystic ovary syndrome	8.6e-06	6.03e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.53e-06	5.98e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	8.51e-06	5.97e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	8.49e-06	5.96e-05	CbGpPWpGaD
Fenoldopam—DRD2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	8.49e-06	5.96e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	8.44e-06	5.92e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—ATF1—polycystic ovary syndrome	8.42e-06	5.91e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—CYP1A1—polycystic ovary syndrome	8.37e-06	5.88e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.36e-06	5.87e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—AKT2—polycystic ovary syndrome	8.36e-06	5.87e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—GNAS—polycystic ovary syndrome	8.3e-06	5.83e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.23e-06	5.78e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.22e-06	5.77e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	8.2e-06	5.76e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	8.2e-06	5.76e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	8.18e-06	5.74e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—NGFR—polycystic ovary syndrome	8.07e-06	5.66e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—POMC—polycystic ovary syndrome	8.02e-06	5.63e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PRL—polycystic ovary syndrome	8e-06	5.61e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.91e-06	5.55e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	7.9e-06	5.55e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	7.86e-06	5.52e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	7.83e-06	5.49e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—MTHFR—polycystic ovary syndrome	7.81e-06	5.48e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—NGFR—polycystic ovary syndrome	7.77e-06	5.46e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—NRG1—polycystic ovary syndrome	7.76e-06	5.45e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—GNAS—polycystic ovary syndrome	7.75e-06	5.44e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—POMC—polycystic ovary syndrome	7.73e-06	5.42e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.71e-06	5.41e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PRL—polycystic ovary syndrome	7.7e-06	5.41e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	7.63e-06	5.36e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—GNAS—polycystic ovary syndrome	7.63e-06	5.36e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	7.6e-06	5.33e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.59e-06	5.32e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	7.53e-06	5.29e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—IRS2—polycystic ovary syndrome	7.46e-06	5.24e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.43e-06	5.21e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.39e-06	5.18e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—IRS2—polycystic ovary syndrome	7.36e-06	5.17e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.31e-06	5.13e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—LEP—polycystic ovary syndrome	7.3e-06	5.13e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.27e-06	5.1e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	7.25e-06	5.09e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	7.22e-06	5.07e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—LEP—polycystic ovary syndrome	7.21e-06	5.06e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	7.18e-06	5.04e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	7.17e-06	5.04e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	7.16e-06	5.02e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—NRG1—polycystic ovary syndrome	7.13e-06	5.01e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	7.03e-06	4.94e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling by GPCR—IL6—polycystic ovary syndrome	6.95e-06	4.87e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.9e-06	4.84e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	6.8e-06	4.77e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.79e-06	4.77e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	6.78e-06	4.76e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.7e-06	4.7e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	6.65e-06	4.67e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	6.58e-06	4.62e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	6.51e-06	4.57e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	6.51e-06	4.57e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.46e-06	4.53e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—IRS1—polycystic ovary syndrome	6.43e-06	4.51e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	6.34e-06	4.45e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	6.34e-06	4.45e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	6.33e-06	4.44e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	6.3e-06	4.42e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—POMC—polycystic ovary syndrome	6.27e-06	4.4e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	6.24e-06	4.38e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—INS—polycystic ovary syndrome	6.24e-06	4.38e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	6.21e-06	4.36e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—INS—polycystic ovary syndrome	6.21e-06	4.36e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—POMC—polycystic ovary syndrome	6.19e-06	4.34e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—INS—polycystic ovary syndrome	6.16e-06	4.32e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	6.11e-06	4.29e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	6.08e-06	4.27e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	6.03e-06	4.24e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	6.03e-06	4.23e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	6e-06	4.21e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	5.98e-06	4.2e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—IGF1—polycystic ovary syndrome	5.95e-06	4.18e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—AKT2—polycystic ovary syndrome	5.95e-06	4.18e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.93e-06	4.16e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	5.89e-06	4.13e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	5.8e-06	4.07e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.73e-06	4.02e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.65e-06	3.97e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	5.63e-06	3.95e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	5.59e-06	3.92e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	5.56e-06	3.9e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	5.51e-06	3.87e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	5.43e-06	3.81e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	5.42e-06	3.8e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	5.38e-06	3.77e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	5.37e-06	3.77e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	5.34e-06	3.74e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	5.31e-06	3.73e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	5.22e-06	3.66e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	5.19e-06	3.64e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	5.14e-06	3.61e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	5.14e-06	3.61e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	5.11e-06	3.59e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.1e-06	3.58e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	5.07e-06	3.56e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	5.04e-06	3.54e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—INS—polycystic ovary syndrome	5.04e-06	3.54e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	5.02e-06	3.52e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	5.02e-06	3.52e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	4.94e-06	3.47e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	4.94e-06	3.47e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	4.94e-06	3.46e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	4.92e-06	3.45e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.77e-06	3.35e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	4.74e-06	3.33e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	4.74e-06	3.32e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	4.71e-06	3.31e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.69e-06	3.29e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	4.61e-06	3.24e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	4.56e-06	3.2e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	4.56e-06	3.2e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling by GPCR—IL6—polycystic ovary syndrome	4.55e-06	3.2e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	4.55e-06	3.2e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	4.54e-06	3.19e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	4.4e-06	3.09e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	4.39e-06	3.08e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	4.39e-06	3.08e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.33e-06	3.04e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	4.24e-06	2.98e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	4.22e-06	2.96e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.17e-06	2.93e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	4.11e-06	2.89e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—IL6—polycystic ovary syndrome	4.1e-06	2.88e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	4.08e-06	2.86e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	4.08e-06	2.86e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.94e-06	2.77e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.89e-06	2.73e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.87e-06	2.72e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	3.84e-06	2.7e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	3.78e-06	2.65e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.51e-06	2.46e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	3.48e-06	2.45e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.36e-06	2.36e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.28e-06	2.3e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.23e-06	2.27e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.12e-06	2.19e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.98e-06	2.09e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.87e-06	2.01e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	2.73e-06	1.91e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—IL6—polycystic ovary syndrome	2.69e-06	1.89e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.66e-06	1.87e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	2.43e-06	1.7e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	2.27e-06	1.59e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	2.23e-06	1.57e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	2.06e-06	1.44e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.98e-06	1.39e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.84e-06	1.29e-05	CbGpPWpGaD
